Brief ReportA Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib
Keywords
Cited by (0)
Disclosure: Dr. Burley has received grants from the National Institutes of Health, the National Science Foundation, and the Department of Energy. Dr. Yu has received grants from Astra Zeneca, Lilly, Novartis, and Daiichi; and has received personal fess from Astra Zeneca and Lilly. Dr. Pine has received grants from the National Institutes of Health and the American Lung Association. Dr. Ganesan has received grants from the National Institutes of Health, the AHEPA Charitable Fund, Roche, Foghorn Therapeutics, Foundation Medicine, Merck, and Inspirata. The remaining authors declare no conflict of interest.
Conflict of interest disclosure statement: Shridar Ganesan has received support from Roche, Foghorn Therapeutics, Foundation Medicine, Merck and Inspirata. Helena Yu has consulted for AstraZeneca and has received travel compensation from Lilly. Her institution has received financial support for clinical research she is involved in from AstraZeneca, Lilly, Novartis, Daiichi, Astellas, and Pfizer. The other authors declare no potential conflicts of interest.